BNT162b2 mRNA vaccination did not prevent an outbreak of SARS COV-2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity

Benoit Bailly1,2, Luc Guilpain3, Kevin Bouiller2,4, Catherine Chirouze2,4 Melissa N’Debi5, Alexandre Soulier6, Vanessa Demontant5, Jean-Michel Pawlotsky6,7, Christophe Rodriguez5,6,7, Slim Fourati6,7

1Department of infectious disease, University Hospital of Besançon, F-25000 Besançon, France; 2Department of infectious disease, hospital of Lons Le Saunier, F-39000 Lons Le Saunier, France. 3Department of medical laboratory, hospital of Lons Le Saunier, F-39000 Lons Le Saunier, France. 4UMR-CNRS 6249 Chrono-environnement, Université Bourgogne Franche-Comté, 25000 Besançon, France. 5Genomics Platform, Hôpital Henri Mondor (AP-HP), Université Paris-Est, Créteil, France; 6Virology Unit, Department of Prevention, Diagnosis and Treatment of Infections, Hôpital Henri Mondor (AP-HP), Université Paris-Est, Créteil, France; 7Institut Mondor de Recherche Biomédicale, INSERM U955, Université Paris-Est, Créteil, France

Corresponding author :
Slim FOURATI, MD, PhD
Virology Unit, Department of Prevention, Diagnosis and Treatment of Infections, Hôpital Henri Mondor (AP-HP), Université Paris-Est, Créteil, France;
Institut Mondor de Recherche Biomédicale, INSERM U955, Université Paris-Est, Créteil, France

Phone : (+33) 1 45 17 81 45
Fax : (+33) 1 49 81 28 39
Email : slim.fourati@aphp.fr

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Alternate corresponding author:

Dr BAILLY Benoît, MD

Department of infectious disease, University Hospital of Besançon, F-25000 Besançon, France

Department of infectious disease, hospital of Lons Le Saunier, F-39000 Lons Le Saunier, France

Phone (1) : +33 3 81 21 87 97 (Besançon)

Phone (2) : +33 3 84 35 60 00 (Lons Le Saunier)

Email : bbailly@chu-besancon.fr
Abstract

We report an outbreak of SARS-CoV-2 501Y.V2 in a nursing home. All non-vaccinated residents (5/5) versus half of those vaccinated with BNT162b2 (13/26) were infected. Two of 13 vaccinated versus 4 of 5 non-vaccinated residents presented severe disease. BNT162b2 did not prevent the outbreak, but reduced transmission and disease severity.

**keywords:** SARS CoV-2, outbreak, variant, BNT162b2 vaccine, nursing home
Introduction

On December 27th, 2020, France started its vaccination campaign in nursing homes using the BNT162b2 mRNA vaccine (Pfizer). At approximately the same time, the emergence of SARS-CoV-2 variant 501Y.V2 has been reported in South Africa and the virus quickly spread throughout Europe (1). We describe here an outbreak related to SARS-CoV-2 variant 501Y.V2 occurring in an elderly nursing home in France after a vaccination campaign with the BNT162b2 mRNA vaccine.

Methods

The study included 31 residents and 59 staff members from a nursing home unit located in Jura, East of France, prospectively followed for 3 weeks after a resident had been diagnosed with COVID-19. All residents and staff members were systematically tested at baseline by RT-qPCR. The tests were repeated in case of symptoms occurring during the following days, and every 7 days until no further cases were found to be positive in the nursing home. All SARS CoV-2 RNA-positive samples were sequenced (full-length genome sequence analysis by means of next-generation sequencing) by the national SARS CoV-2 sequencing platform located at the Henri Mondor virology laboratory, one of the 4 platforms involved in the French national SARS-CoV-2 genomic surveillance program. Antibodies targeting both the nucleoprotein and the RBD domain of the spike protein were sought by means of enzyme immunoassay at the time of COVID-19 diagnosis in all of the vaccinated individuals. Our study protocol followed the ethical guidelines of the declaration of Helsinki and was approved by our institutional review board (N° IRB 00011558-2021-107). No additional tests were performed outside routine care in agreement with the “Agence Régionale de Santé” (ARS) and the medical support team. Data collection was performed as part of routine care.
by the medical staff. Antibody assays were performed at the request of the ARS in order to evaluate vaccine efficacy.

**Results**

On March 8th, 2021, a fully vaccinated 92-years old resident presented with abdominal pain, fever and diarrhea. SARS CoV-2 RNA was detected in a nasopharyngeal swab (NPS) sampled on the same day. Full-length viral genome sequence analysis identified a 501Y.V2 variant. From March 8th to March 29th, 17 additional residents were tested SARS CoV-2 RNA-positive in their NPSs. Full-length genome sequence analysis was performed in 10 of them and all were infected with SARS CoV-2 variant 501Y.V2. Phylogenetic analysis showed that their genome sequences were all closely related (Supplementary Figure 1), carrying the same amino acid pattern, including spike mutations L18F, D80A, D215G, Del-L242, Del-A243, Del-L244, K417N, E484K, N501Y, D614G, A701V. All sequences were submitted to GISAID database.

At the time of the study, 26 out of the 31 residents (83.9%), mean age: 87.0±8.2 years, 64.5% of females, had been fully vaccinated with 2 successive doses of the BNT162b2 mRNA vaccine 19 days apart. The second dose was administered to all of them between the 4th and the 26th of February 2021 (Table 1). The 5 remaining residents had not been vaccinated. Thirteen of the 26 fully vaccinated residents (50.0%) versus all of the 5 non-vaccinated residents (100%) were infected during the outbreak (p=0.058, Fisher’s exact test). Thus, vaccination efficacy against SARS-CoV-2 infection was 50.0% (95% confidence interval: 34% to 73%). Among the 13 fully vaccinated residents who were infected, 2 (15.4%) presented with an asymptomatic disease, 9 (69.2%) developed mild to moderate symptoms, and 2 (15.4%) progressed to severe disease with fatal evolution secondary to acute respiratory distress syndrome (ARDS). The 2 latter patients had chest CT scans showing bilateral patchy peripheral ground glass opacities. The group of vaccinated residents had varying
levels of anti-S antibodies at diagnosis (median: 1169 AU/mL, range: <6.8-8188 AU/mL, Table 1), with no relationship with disease severity. Among the 5 non-vaccinated residents, 4 (80%) progressed to severe disease, including a resident with a recent history of COVID-19. One of them died. Overall, the proportion of residents with severe disease in the non-vaccinated group (4/5) was higher than that in the vaccinated group (2/13). The SARS CoV-2 viral load, estimated by the mean cycle threshold (Ct) value, was significantly higher in non-vaccinated residents (mean Ct: 15, range 12-17) than in vaccinated residents (mean Ct: 21, range: 13-32; p<0.05, Student t test).

Among the 59 staff members tested, 19 (32.2%) had been vaccinated with 2 doses of the BNT162b2 mRNA vaccine, while 4 (6.8%) had a history of prior COVID-19 confirmed by RT-qPCR. Only 1 vaccinated staff member (5.2%) versus 10 non-vaccinated staff members (25.0%) were ultimately infected (p=0.085, Fisher’s exact test). No infected staff member developed severe disease.

**Discussion**

We report here the first description of an outbreak related to SARS-CoV-2 variant 501Y.V2 in an elderly nursing home in which more than 80% of residents had received two injections of the BNT162b2 mRNA vaccine. All but one of the vaccinated residents had received the second vaccine dose more than one month before the outbreak. The remaining one had received the second dose 11 days before. All but one of the infected residents who had been vaccinated had detectable anti-S antibodies at the time of diagnosis, at levels ranging from 79 to 8188 UA/mL. According to the nationwide vaccination survey performed in Israel after BNT162b2 vaccination has been massively administered to their population, the efficacy of the vaccine after the second dose was 92% and 94% against documented infection and symptomatic disease, respectively (2). Subgroup analysis showed
that vaccine efficacy was similar for adults more than 70 years of age. However, circulation of SARS CoV-2 variant 501Y.V2 is low in Israel. Thus, the effect of vaccination on this variant could not be evaluated. In another study, Benenson et al. reported high efficacy of vaccination with BNT162b2 in a population of healthcare workers predominantly infected with SARS-CoV-2 variant B.1.1.7/501Y.V1 (but not 501Y.V2) (3).

Preliminary reports from clinical trial efficacy suggested reduced protection of the vaccines against variant 501Y.V2 as compared to other variants. AZD1222 efficacy was only 22% according to preliminary data from South Africa (4). In a South-African study, the efficacy of NVX-CoV237 was 49% (5) and that of Ad26.COV2-S was 57% (6). Thus far, there is limited data regarding the clinical efficacy of BNT162b2 vaccination against variant 501Y.V2. Kustin et al. observed an increased incidence of 501Y.V2 among vaccine breakthrough infections in individuals fully vaccinated with BNT162b2 after mass vaccination in Israel (7). An outbreak with a SARS-CoV2 R.1 lineage harboring the Spike E484K substitution has been reported in a nursing home after vaccination with BNT162b2. In this study, the estimated vaccination efficacy against SARS-CoV2 infection among residents was 66.2% (8), similar to that observed against SARS CoV-2 501Y.V2 in our study (50.0%). Our study also suggests that vaccination is associated with reduced SARS CoV-2 viral loads in the upper respiratory tract in case of infection by 501Y.V2, thus possibly with reduced contagiousness. Our study is thus the first to confirm partial effectiveness of BNT162b2 vaccination against 501Y.V2 variant infection an elderly population. These results remain to be confirmed as our study is observational with a limited sample size.

*In vitro* studies have documented escape of the 501Y.V2 variant from serum neutralizing antibody responses acquired after BNT162b2 vaccination. Reduced sensitivity to neutralization was mainly due to the acquisition of amino-acid substitutions in the spike RBD domain, including K417N, E484K and N501Y (9,10). In contrast, adaptive T-cell responses, which play a role in the modulation of COVID-19 severity, do not seem to be affected by these mutations. This could explain the small
number of severe cases in the vaccinated resident group. In our cohort, the case fatality rate of fully vaccinated residents was similar to the fatality rate observed in nursing homes before the vaccination campaign (11), although severity was greater in unvaccinated compared to vaccinated residents. Larger observational studies are urgently needed to confirm these results.

The low COVID-19 vaccination coverage of staff members in this study (32.2%) was similar to the national rate of vaccination coverage in healthcare workers during the same period (25%) (12). In France, non-compulsory vaccination adhesion is usually low among healthcare workers (13,14). SARS-CoV-2 vaccination of visitors and healthcare workers is now being actively promoted, as recommended by the French National Academy of Medicine in all healthcare workers.

Several studies reported a major impact of social isolation on mental health in nursing homes, where restrictive measures can increase depression, anxiety and worsen dementia (15,16). In this context, some of these restrictions were removed after vaccination. Our study shows that vaccination of residents in nursing homes may not be sufficient to prevent outbreaks with emerging variants, such as 501Y.V2, that may escape the action of neutralizing antibodies induced by currently available vaccines. Weekly symptom screening and viral testing of residents, visitors, and staff members should be maintained even after vaccination campaigns to preempt and identify outbreaks of emerging variants.
**Acknowledgements:** Ms Yannick Charriere and all staff members of the nursing home, for follow up and the care given to the residents

**Funding source disclosure statement:** Funding was provided by the ministry of health in the context of a French surveillance program for SARS CoV-2 genomic evolution

**Conflict of interest disclosures**

S.F. has served as a speaker for MSD, Abbvie and Abbott diagnostics. J.-M.P. has served as an advisor, and/or speaker for Abbvie, Gilead, GlaxoSmithKline, Merck, Regulus, and Siemens Healthcare. N.D. The remaining authors have no conflict of interest to disclose.
References

1. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 22 déc 2020;2020.12.21.20248640.

2. Dagan N, Bara N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 15 avr 2021;384(15):1412-23.

3. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 5 juill 2018;379(1):22-31.

4. Madhi SA, Baillie V, Cutland CL, Vousey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 16 mars 2021;

5. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial | Novavax Inc. - IR Site [Internet]. [cité 26 mars 2021]. Disponible sur: https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3

6. Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial | Johnson & Johnson [Internet]. Content Lab U.S. [cité 26 mars 2021]. Disponible sur: https://www.jnj.com/johnson-and-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial

7. Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. medRxiv. 9 avr 2021;2021.04.06.21254882.

8. Cavanaugh AM, Fortier S, Lewis P, Arora V, Johnson M, George K, et al. COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program - Kentucky, March 2021. MMWR Morb Mortal Wkly Rep. 30 avr 2021;70(17):639-43.

9. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. BioRxiv Prepr Serv Biol. 19 janv 2021;

10. Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 23 févr 2021;

11. Hashan MR, Smoll N, King C, Ockenden-Muldoon H, Walker J, Wattriaux A, et al. Epidemiology and clinical features of COVID-19 outbreaks in aged care facilities: A systematic review and meta-analysis. EClinicalMedicine. 1 mars 2021;100771.

12. Données relatives aux professionnels de santé vaccinés contre la Covid-19 (VAC-SI) - data.gouv.fr [Internet]. [cité 1 mai 2021]. Disponible sur: /fr/datasets/donnees-relatives-aux-professionnels-de-sante-vaccines-contre-la-covid-19/
13. Vaux S, Noël D, Fonteneau L, Guthmann J-P, Lévy-Bruhl D. Influenza vaccination coverage of healthcare workers and residents and their determinants in nursing homes for elderly people in France: a cross-sectional survey. BMC Public Health. 25 mars 2010;10:159.

14. Guthmann J-P, Fonteneau L, Ciotti C, Bouvet E, Pellissier G, Lévy-Bruhl D, et al. Vaccination coverage of health care personnel working in health care facilities in France: results of a national survey, 2009. Vaccine. 29 juin 2012;30(31):4648-54.

15. Galea S, Merchant RM, Lurie N. The Mental Health Consequences of COVID-19 and Physical Distancing: The Need for Prevention and Early Intervention. JAMA Intern Med. 1 juin 2020;180(6):817-8.

16. Abbasi J. Social Isolation-the Other COVID-19 Threat in Nursing Homes. JAMA. 16 juill 2020;
Table 1. Clinical and biological characteristics of vaccinated and non-vaccinated residents infected with SARS-CoV-2 variant 501Y.V2.

| Vaccinated residents | Age | Underlying conditions* | Date of the last dose of BNT162b2 | Date of RT-PCR + | Onset symptom | Anti-S antibodies (Architect, Abbott UA/mL) | Anti-N antibodies (Architect, Abbott, index) | Illness Severity |
|-----------------------|-----|------------------------|-----------------------------------|-----------------|--------------|-------------------------------------------|-------------------------------------------|-----------------|
| Resident 1            | 92  | DM HC                  | 02 February                       | 08 March        | 13           | 04 march                                   | 139                                        | <1,4           | Death          |
| Resident 2            | 95  | HC Hypertension        | 02 February                       | 09 March        | 19           | 11 march                                   | 79                                         | <1,4           | mild to moderate |
| Resident 3            | 69  | CD Cancer NC           | 02 February                       | 09 March        | 20           |                                            | 3364                                      | <1,4           | Asymptomatic |
| Resident 4            | 88  | Obesity T2DM HC Hypertension | 02 February                       | 09 March        | 17           | 11 march                                   | 643                                        | <1,4           | Death          |
| Resident 5            | 89  | T2DM HC Hypertension COPD NC | 02 February                       | 09 March        | 32           | 11 march                                   | 3298                                      | <1,4           | mild to moderate |
| Resident 6            | 99  | HC NC                  | 02 February                       | 09 March        | 19           |                                            |                                            | <1,4           | mild to moderate |
| Resident | Age | Condition   | Onset | First Symptom | First Diagnosis | Days to Diagnosis | Diagnosis Code | Severity |
|----------|-----|-------------|-------|---------------|----------------|------------------|----------------|---------|
| Resident 7 | 89  | HC Hypertension | 02 February | 09 March | 14 | 09 march | 2683 | <1,4 | mild to moderate |
| Resident 8 | 95  | HC cancer | 02 February | 09 March | 29 | 12 march | 599 | <1,4 | mild to moderate |
| Resident 9 | 97  | Hypertension NC | 02 February | 09 March | 32 |           | 867 | <1,4 | Asymptomatic |
| Resident 10 | 80 | T2DM | 02 February | 11 March | 29 | 11 march | 4903 | <1,4 | mild to moderate |
| Resident 11 | 87 | NC | 02 February | 15 March | 18 | 11 march | 8188 | <1,4 | mild to moderate |
| Resident 12 | 83 | NC Hypertension | 02 February | 15 March | 15 | 12 march | 1471 | <1,4 | mild to moderate |
| Resident 13 | 93 | Hypertension | 26 February | 22 March | 17 | 15 march | 550 | <1,4 | mild to moderate |

**Unvaccinated resident**

| Resident 14 | 77 | NC COPD | - | 09 March | 17 | 09 March | - | Severe |
| Resident 15 | 88 | NC HC Hypertension | - | 09 March | 13 | 09 March | - | Death |
| Resident 16 | 83 | NC | - | 09 March | 12 | 10 March | - | mild to moderate |
| Resident 17 | 81 | Obesity Hypertension | - | 09 March | 16 | 10 March | - | Severe |
| Resident 18 | 92 | NC CD | - | 09 March | 17 | 10 March | - | Severe |

* Underlying conditions increased risk for severe illness according CDC. HC: heart condition such as heart failure, coronary artery disease, or cardiomyopathies. T2DM: Type 2 T2DM. CD: Cerebral disease (affects blood vessels and blood supply to the brain). NC: Neurologic conditions, such as dementia.